Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Kazdal

Showing results (61-70 of 116) with videos related to

Pageof 12
Sort By:
Translational Lung Cancer Research|June 24, 2021
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsiesPetros Christopoulos, Steffen Dietz, Arlou K Angeles, et al.
British Journal of Cancer|June 12, 2024
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinomaJan Budczies, Eva Romanovsky, Martina Kirchner, et al.
Genes, Chromosomes & Cancer|February 28, 2023
Real-world data for precision cancer medicine-A European perspectivePetros Christopoulos, Richard Schlenk, Daniel Kazdal, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 12, 2019
Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated GenesClemens Kratochwil, Frederik L Giesel, Claus-Peter Heussel, et al.
Cold Spring Harbor Molecular Case Studies|January 21, 2022
Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case reportMarkus Ball, Petros Christopoulos, Martina Kirchner, et al.
Frontiers in Oncology|April 26, 2021
<i>De Novo</i> Versus Secondary Metastatic <i>EGFR</i>-Mutated Non-Small-Cell Lung CancerFarastuk Bozorgmehr, Daniel Kazdal, Inn Chung, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2024
Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world studyGabriel Dernbach, Daniel Kazdal, Lukas Ruff, et al.
The Journal of Molecular Diagnostics : JMD|March 24, 2024
Leveraging Off-Target Reads in Panel Sequencing for Homologous Recombination Repair Deficiency Screening in TumorMarkus Ball, Iordanis Ourailidis, Klaus Kluck, et al.
International Journal of Cancer|January 24, 2020
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primaryTilmann Bochtler, Anna Reiling, Volker Endris, et al.
Genes, Chromosomes & Cancer|March 27, 2020
Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencingSuranand B Talla, Eugen Rempel, Volker Endris, et al.
Pageof 12

Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
Translational Lung Cancer Research|June 24, 2021
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsiesPetros Christopoulos, Steffen Dietz, Arlou K Angeles, et al.
British Journal of Cancer|June 12, 2024
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinomaJan Budczies, Eva Romanovsky, Martina Kirchner, et al.
Genes, Chromosomes & Cancer|February 28, 2023
Real-world data for precision cancer medicine-A European perspectivePetros Christopoulos, Richard Schlenk, Daniel Kazdal, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 12, 2019
Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated GenesClemens Kratochwil, Frederik L Giesel, Claus-Peter Heussel, et al.
Cold Spring Harbor Molecular Case Studies|January 21, 2022
Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case reportMarkus Ball, Petros Christopoulos, Martina Kirchner, et al.
Frontiers in Oncology|April 26, 2021
<i>De Novo</i> Versus Secondary Metastatic <i>EGFR</i>-Mutated Non-Small-Cell Lung CancerFarastuk Bozorgmehr, Daniel Kazdal, Inn Chung, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2024
Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world studyGabriel Dernbach, Daniel Kazdal, Lukas Ruff, et al.
The Journal of Molecular Diagnostics : JMD|March 24, 2024
Leveraging Off-Target Reads in Panel Sequencing for Homologous Recombination Repair Deficiency Screening in TumorMarkus Ball, Iordanis Ourailidis, Klaus Kluck, et al.
International Journal of Cancer|January 24, 2020
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primaryTilmann Bochtler, Anna Reiling, Volker Endris, et al.
Genes, Chromosomes & Cancer|March 27, 2020
Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencingSuranand B Talla, Eugen Rempel, Volker Endris, et al.
Pageof 12